Relmada Therapeutics RLMD
NASDAQ RLMD
$4.27 +0.13 (+3.14%)
At close: Nov 10, 2026 · 4:00 PM EST

Relmada Therapeutics (RLMD) EBITDA Margin (2015 - 2021)

Updated

Relmada Therapeutics (RLMD) posted EBITDA Margin of -95047.20% for Q4 2021, down 85717.90 percentage points from -9329.30% a year earlier.

Analysis

Relmada Therapeutics (RLMD) EBITDA Margin (2015 - 2021) Analysis & Trends

For FY2021, Relmada Therapeutics' EBITDA Margin came in at -22324.64%.

  • Annual EBITDA Margin shows a five-year change of +902732.83 percentage points (FY2016 to FY2021).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 54.65%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 32.68%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 46.88%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 40.75%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 46.62%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 50.63%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 42.49%
10 Relmada Therapeutics 473.10 Mn -85.48 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -95,047.20%
Dec 31, 2020 -9,329.30%
Sep 30, 2020 -5,307.09%
Sep 30, 2019 -9,775.06%
Mar 31, 2019 -16,945.41%
Sep 30, 2017 -176.91%
Jun 30, 2017 -856,614.08%
Mar 31, 2017 -477,734.46%
Jun 30, 2016 -162,506.96%
Mar 31, 2016 -349,552.44%
Jun 30, 2015 -925,297.76%
API Access

Relmada Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RLMD&period=max&api_key=YOUR_API_KEY